Managing the Risks of Government-Run Healthcare Systems: Mitigating Global Corruption and More Potential Exposure in Drug and Device Research, Testing and Approvals in Foreign Jurisdictions
Ash Aggarwal
Principal, Global Commercial Compliance
IQVIA (UK)
Tarek Helou
Partner
Wilson Sonsini Goodrich & Rosati
Former Assistant Chief, FCPA Unit, Fraud Section, Criminal Division,
U.S. Department of Justice
- Understanding where the biggest vulnerabilities lie in drug and device research and testing within government-run healthcare systems
- Best practices for monitoring and mitigating risks associated with clinical research/trials in foreign jurisdictions
- Navigating the blurred lines of what qualifies as “improper influence” of clinical investigators, ethics committee members, trial data results and the approval process
- Safeguarding against unique corruption risks associated with clinical trial funding, patient recruitment, the informed consent process, and dealings with third-party research organizations / CROs